Document series
Trial abstracts — page 11
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 11 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| DANU-PH2B-T2D-REGIONAL-JPprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-BODY-COMPprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-QOLprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| OASIS-1-ADHERENCEprogramme record | Semaglutide, oral | Phase 3 | Reported | Observational | — | 2023 | Very low |
| OASIS-1-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| OASIS-1-OLEprogramme record | Semaglutide, oral | Phase 3 | Reported | Single-arm open-label | — | 2023 | Very low |
| ORFO-PH2-OBESITY-QOLprogramme record | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-OBESITY-REGIONAL-CNprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-OBESITY-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-T2D-DDIprogramme record | Orforglipron | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| ORFO-PH2-T2D-HEPATIC-IMPprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-T2D-PKprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-OBESITY-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-T2D-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| RETA-PH2-T2D-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SELECT-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2023 | Very low |
page 11 of 30